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Antigens specific for individual tumors were first discovered in experiments 
that showed the rejection of chemically induced sarcomas in mice and rats that 
had been immunized with the same tumor (1). Subsequently, individually distinct 
antigens  were also  found  in  transplantation  studies of murine reticulum cell 
sarcomas and mammary tumors.  Detailed study of these unique antigens has 
long been hampered by the considerable difficulties encountered in attempts to 
detect them in vitro. Success was first reported in a study of the methylcholan- 
threne-induced BALB/c sarcoma Meth A. Hyperimmunization ofsyngeneic mice 
with this tumor resulted in the production of antibodies recognizing a cell surface 
antigen whose expression showed the same restriction as the antigen detected in 
transplantation experiments (2).  More recent serological studies of feline leuke- 
mias, and of murine sarcomas induced by the  Rous sarcoma virus,  have also 
defined individually distinct cell surface antigens expressed only on the tumor 
used for immunization. With the advances in the serological analysis of human 
tumors brought  about  by the development of autologous typing,  unique  cell 
surface antigens have also been found on human cancers--melanoma, astrocy- 
toma, and renal cancer (2). 
Although individually distinct tumor antigens were initially shown  in  trans- 
plantation experiments generally considered to reflect cellular immunity, there 
have only been a  few reports describing recognition of unique tumor antigens 
by cytotoxic T  cells in vitro (3,  4).  We report here that  leukemias induced in 
mice  by  the  radiation  leukemia  virus  (RadLV)  express  individually  distinct 
antigens  recognized by cytotoxic T  cells,  in  addition  to  crossreacting tumor- 
specific antigens detected in transplantation experiments. 
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Materials and Methods 
Mice.  The following mouse strains were used: BALB/c, C57BL/6 (B6), and their Fj 
hybrids (Memorial Sloan-Kettering  Cancer  Center, New York); BALB/c Cr Sic, B6 Cr 
Sic, and their F~ hybrids (Agricultural Cooperative Association, Shizuoka,Japan); BALB/c 
NCr, B6 NCr (Charles River Breeding Laboratories  Inc., Wilmington, MA). 
RadLV Leukemias.  B6  mice and BALB/c mice,  1-4  d  old,  were  injected  i.p. with 
RadLV (5, 6). Leukemias developed in 83% of the B6 mice and in 64% of the BALB/c 
mice. They were maintained in serial transplantation  in syngeneic mice, and in stationary 
suspension culture in RPMI-1640 medium supplemented with 10% FCS. 
Antisera.  mAbs specific for Thy-l.2, Lyt-l.2, Lyt-2.2, and Lyt-3.2 antigens were used; 
these antibodies have been described (7). 
In Vitro Sensitization of Spleen Cells.  As described  previously (4). At the end of the 
incubation period the cells were harvested and used as effector cells in ~Cr release assays 
for cell-mediated cytotoxicity (5~Cr-CMC assays). 
Assays and Cell Treatments.  ~Cr-CMC assays and competitive inhibition assays, as well 
as elimination of effector cell subpopulations by antiserum and complement were done as 
previously described (4). 
Results 
Resistance  to  Transplants  of RadLV  Leukemias  in  Semisyngeneic  FI  Hybrid 
Mice.  12  RadLV-induced leukemias were examined, 3  of B6 origin and 9  of 
BALB/c origin. (BALB/c x  C57BL/6)F~  (CB6F1)  mice were injected subcuta- 
neously with 104 leukemia cells, and mice that rejected this initial inoculum were 
subsequently challenged with increasing numbers of leukemia cells.  Rejection of 
the initial leukemia ceil inoculum was observed with leukemias B6RV2, B6RV4, 
BALBRV1, BALBRVA, BALBRVB, and BALBRVD, but not with leukemias 
B6RV1, BALBRV2, BALBRV3, BALBRV4, BALBRVC, and BALBRVE. Leu- 
kemias BALBRVB and BALBRVD were induced in  male BALB/c mice, and 
rejected by female mice but not by male mice, a finding that raises the possibility 
that  male antigens contributed  to  immunological recognition.  In  the  case  of 
leukemias BALBRV1 and BALBRVA, which were induced in female mice, this 
possibility need not be considered. 
Resistance  to Tumor Grafts After Rejection  of RadLV Leukemias.  Female CB6FI 
mice injected subcutaneously with 5 x  105 BALBRVB or BALBRVD leukemia 
cells  showed  initial  growth  and  subsequent  regression  of the  leukemia  cell 
inoculum.  Most  male  CB6F~  mice  showed  progressive  tumor  growth.  After 
rejection of BALBRVB or BALBRVD leukemia cells, mice were challenged with 
RadLV leukemias, radiation-induced leukemias, leukemia LSTRA (induced by 
the  Moloney virus),  or  the  methylcholanthrene-induced sarcoma  Meth A, all 
originating in female BALB/c mice except BALBRVB and BALBRVD, which 
were induced in  male  mice.  Mice  that  had  rejected leukemias BALBRVB or 
BALBRVD  showed  growth  inhibition  of  RadLV  ieukemias  BALBRVB, 
BALBRVD,  BALBRV1,  BALBRV2,  and  BALBRV3,  and  of the  radiation- 
induced leukemia RL~?8. No inhibition of tumor growth was seen in mice chal- 
lenged with leukemia RL~6, leukemia LSTRA, or sarcoma Meth A (Table I). 
Specificity of Cytotoxic CB6F~ Effector  Cells  Generated  Against RadLV Leukemias 
BALBRVB and  BALBRVD: Results  of Direct  Tests  and  Competitive  Inhibition  As- 
says.  Spleen cells were obtained from CB6Fl mice 2 wk after complete rejection 
of leukemia BALBRVB, and sensitized in vitro with BALBRVB leukemia cells. 
Results  of direct  tests  with  such  cytotoxic effectors are  shown  in  Table  II. 454  MORISHITA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  | 
Grossreactivity of Transplantation Immunity Against RadL V 
Leukemias 
Tumor used for challenge  Rejection 
BALBRVB  + 
BALBRVD  + 
BALBRV 1  + 
BALBRV2  + 
BALBRV3  + 
RL96 
RL98  + 
LSTRA 
Meth A 
After rejecting BALBRVB or BALBRVD, female CB6FI mice were challenged with 
5 ×  I0 ~ viable tumor cells. 
TABLE  II 
Cytotoxicity of CB6F1 Effector Cells Generated Against RadLV Leukemias 
BALBRVB or BALBRVD: Results of Direct Tests 
Effector cells  Target cells 
Percent specific lysis 
20*  10  5  2.5  1.2  0.6 
CB6F~  anti-BALBRVB* 
CB6F~ anti-BALBRVD  *~ 
BALBRVA  5  1  0  0  0  0 
BALBRVB  50  48  44  40  39  27 
BALBRVC  8  0  0  0  0  0 
B6RV2  1  0  0  0  0  0 
BALBRVA  0  0  0  0  0  0 
BALBRVB  15  10  5  6  7  -- 
BALBRVC  0  0  0  0  0  -- 
BALBRVD  76  74  64  49  46  42 
* E/T cell ratio; 2  ×  104 SlCr-labeled target cells were used. 
* Spleen cells from mice that had rejected leukemia BALBRVB or BALBRVD were sensitized 
in vitro with BALBRVB  or BALBRVD cells, respectively. 
Cytotoxicity was demonstrable only in tests on the RadLV cells used for immu- 
nization,  not in tests on any other target cells.  These tests included  10 RadLV 
leukemias and Con A  blasts from 12 mouse strains (Table III). 
The specificity of the reaction was further analyzed in competitive inhibition 
assays. Individual tests are shown in Fig.  1. Lysis of BALBRVB leukemia cells by 
effector  cells  against  leukemia  BALBRVB  was  inhibited  only  by  BALBRVB 
leukemia  cells,  not by  other  RadLV  leukemia  cells  or normal spleen  cells and 
thymocytes (A  and B).  Similar  results  were  obtained  in  competitive  inhibition 
assays using effector cells generated against leukemia  BALBRVD  (C and D). A 
summary of results obtained  with  leukemia  BALBRVB  is shown in Table  III. 
The results of competitive inhibition assays with effector cells against leukemia 
BALBRVD  also confirmed the results of direct tests.  In both systems, the only 
cells  that  inhibited  cytotoxic  reactivity  were the leukemia  cells,  BALBRVB  or 
BALBRVD,  against  which  the  effector  cells  had  been  generated,  indicating 
individually distinct specificity  of the antigens recognized  in the cytotoxic reac- 
tion. 
T Cell Characteristics of the Cytotoxic Effector Cells  Generated  Against Leukemias 
BALBRVB and BALBRVD.  The T  cell characteristics  of the cytotoxic effector 
cells  were  defined  in  experiments  eliminating  effector  cell  subpopulations by MORISHITA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  III 
Individually Distinct Specificity  of CB6F I Cytotoxic Effector Cells Reactive 
with RadLV Leukemia BALBRVB: Nonreactive Target Cells in Direct Tests 
and Competitive Inhibition  Tests 
455 
RadLV leukemias  Moloney virus leukemia  Con A blasts 
BALBRVA  BA LB/c LSTRA  BA LB/c 
BALBRVC  B6 
BALBRVD  Methylcholanthrene  sarcomas  C3H/He 
BALBRVE  BALB/c Meth A  SJL/J 
BALBRVI  CMC-I  RIII/2J 
BALBRV2  CMC-I 1  PL/J 
BALBRV3  CMC-I 2  A.CA/Sn 
B6RV 1  CMC- 13  B 10WB/Sn 
B6RV2  C3H.NB/Sn 
B6RV4  Rous virus sarcomas  DBA/1J 
BALB/c C-SA-I M  A/J 
Radiation  leukemias  C-SA-9F  SM/J 
BALB/c  RL~I 
RL96  Myelomas  Spleen cells, thymocytes 
RL98  BALB/c 4T001  BALB/c,  B6 
MPC-I 1 
Comparable results  were obtained in tests with effector  cells generated against  leukemia 
BALBRVD. 
pretreatment with antibodies against T cell differentiation antigens, with addition 
of complement.  Treatment with  Thy-l.2,  Lyt-2.2,  or  Lyt-3.2  antibody com- 
pletely abolished cytotoxic reactivity. Treatment with Lyt-l.2 antibody reduced 
cytotoxic reactivity but did not eliminate it. A significant decrease of cytotoxicity 
was  also  observed  when  Lyt-2.2  or  Lyt-3.2  antibodies  were  added  without 
complement at the start of the cytotoxicity assay. 
Discussion 
We have examined the immune response of mice to RadLV-induced leukemias 
in terms of transplantation immunity in vivo and T  cell cytotoxicity in vitro. It 
appears that the two reactions detect different antigenic systems. CB6F1  female 
mice preimmunized with RadLV leukemias BALBRVB or BALBRVD showed 
growth  inhibition  of  five  RadLV  leukemias  when  subsequently  challenged, 
indicating  the  presence  of tumor-specific transplantation  antigens  shared  by 
leukemias induced by  the  same  virus.  Male  antigens  may play a  role  in  the 
primary rejection of leukemias BALBRVB  and  BALBRVD  (both  induced in 
male mice) by female recipients. They are unlikely to be responsible, however, 
for the secondary rejection in  preimmunized mice, because RadLV leukemias 
derived from female mice were also rejected. 
In contrast to the crossreactivity between RadLV leukemias seen in transplan- 
tation  experiments,  cytotoxic  T  cells  generated  against  RadLV  leukemias 
BALBRVB or BALBRVD recognized only the cells of the leukemias used for 
immunization. Shared antigens were not detected in direct assays or inhibition 
assays on a large panel of leukemias and other tumors of BALB/c origin. Identical 
results were obtained  with  these two  leukemias, indicating that expression of 
individually distinct antigens is  not restricted to a  rare leukemia. Cytotoxic T 
cells generated against murine leukemia virus (MuLV)-induced leukemias have 
been reported to recognize antigens shared by several leukemias induced by the 
same virus  (8-12),  predominantly type- or  subgroup-specific determinants of 456 
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FIGURE  1.  Competitive  inhibition assays  with  effector  cells  generated  against  leukemias 
BALBRVB (A and B) and BALBRVD (C and D).  Unlabeled inhibitor cells were added at 
indicated ratios to 2  X  10  4 SlCr-labeled target cells. E/T ratio was  15:1. Inhibitor cells used: 
®,  none; ©,  BALBRVA;  A,  BALBRVB; 0,  BALBRVC; YT,  BALBRVD;  x,  BALBRVE; A, 
B6RV2; O,  BALB/c thymocytes; II,  BALB/c spleen cells; ",  B6 thymocytes; O,  B6 spleen 
cells. 
gp70 or other viral structural components (8-11). Compared with the extensive 
information that exists regarding the specificity of T cell recognition of leukemias 
induced by Gross and Moloney MuLV, very little is known about RadLV-induced 
leukemias. However, it is clear from our findings and from other observations 
(5) that RadLV leukemias express individually distinct cell surface antigens that 
can be recognized by cytotoxic T  cells. 
An intriguing aspect of the tumor-host relationship observed in this study is 
the difference in specificity between T  cell cytotoxicity (detecting individually 
specific antigens) and transplantation immunity (detecting shared antigens). This 
finding raises questions regarding the role cytotoxic T  cells play in the rejection 
of tumors in vivo. Issues requiring clarification include the phenotypic charac- 
teristics of effector cells in the two reactions, the genetic control of induction of 
effector cell activity, and  the  operation  of genetic restriction  in  effector cell 
function.  Preliminary results suggest that  Lyt-l+,2  + and Lyt-l+,2  -  T  cells are 
required for in vivo transfer of crossreactive resistance to RadLV leukemias, and 
that Lyt-l+,2  ÷ and Lyt-l-,2 + cells participate in the cytotoxic in vitro reaction 
that recognizes unique antigens.  Establishment of cloned effector cell lines in 
continuous culture will be useful in the pursuit of these issues. 
Summary 
The  specificity of transplantation  immunity and  T  cell  cytotoxicity against 
leukemias induced by RadLV was examined. Subcutaneous inoculation of two 
RadLV  leukemias induced in  BALB/c  mice,  BALBRVB and  BALBRVD,  re- 
sulted  in  initial  tumor  growth  in  CB6FI  mice,  followed by  complete  tumor 
regression.  Mice that had rejected leukemias BALBRVB or BALBRVD  were 
subsequently challenged with various tumors of BALB/c origin. The growth of 
all  five RadLV  leukemias tested, and of one radiation-induced leukemia, was 
significantly  inhibited.  Another  radiation-induced  leukemia,  a  methylcholan- 
threne-induced sarcoma, and a leukemia induced by the Moloney leukemia virus, MORISHITA  ET AL.  BRIEF  DEFINITIVE  REPORT  457 
were not inhibited. The results indicate that RadLV leukemias share cell surface 
antigens  that  induce transplantation  immunity  in  vivo.  Cytotoxic lymphocytes 
were generated by cocutturing spleen cells from mice that had rejected leukemia 
BALBRVB or  BALBRVD  with  the  corresponding leukemia cells.  Direct tests 
and  inhibition  tests  showed  that  such  cytotoxic cells  recognized  individually 
specific antigens  on  leukemias  BALBRVB  and  BALBRVD,  distinct  from  the 
shared antigens  detected in  transplantation  experiments.  The effector cells in 
cytotoxicity assays were Thy-1 +, Lyt-1 +'-, Lyt-2  ÷, and Lyt-3  + T  cells. 
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